INM — Mentari Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: InMed Announces Management Changes
InMed Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Inmed Pharmaceuticals Reports $0.31 Loss Per Share In Second Quarter Fiscal 2022
InMed Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Inmed Pharmaceuticals - Files Preliminary Prospectus Relating To Offering And Resale By Selling Shareholder Of Up To 2.1 Million Of Co's Shares
Brief: InMed Pharmaceuticals Announces Publication Of Peer-Reviewed Article On The Use Of Cbn As A Potential Treatment For Glaucoma
InMed Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results
InMed Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: InMed Pharmaceuticals Announces Commencement Of Phase 2 Clinical Trial Investigating Cannabinol In The Treatment Of Epidermolysis Bullosa
NASDAQ RESUMED AT 09:53 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:49 AM
U.S. STOCKS ON THE MOVE-Zivo Bioscience, Accenture, Carnival Corp
InMed Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
InMed Pharma gains on narrower-than-expected loss
InMed Pharmaceuticals Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: InMed Pharmaceuticals Signs Definitive Agreement To Acquire Baymedica
Brief: InMed Pharmaceuticals Files Prelim Prospectus Dated July 12 Related To Offering And Resale By Selling Shareholder Of Up To 8.1 Mln Shares
Brief: InMed Announces Closing Of US$12 Million Private Placement Priced At-The-Market Under Nasdaq Rules